In a report released on January 9, David Evans from Kepler Capital maintained a Hold rating on GlaxoSmithKline (GSK – Research Report), with a ...

In a report released today, Florent Cespedes from Bernstein maintained a Buy rating on GlaxoSmithKline (GSK – Research Report), with a price ...

The approval is based on successful trials demonstrating its efficacy and safety, positioning GSK as a leader in addressing type 2 inflammation-related diseases. More about GlaxoSmithKline GSK is ...

London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves ...

Topline results from the groundbreaking Salford Lung Study are encouraging for GSK's new respiratory drug - but the 'real world' story isn't quite so simple. GlaxoSmithKline (GSK) has announced ...

GlaxoSmithKline (GSK) has firmly acquired the number one position in the Egyptian pharmaceutical market since 2009 and is likely to maintain the grip at least until the end of 2011. GSK’s ...

British pharmaceutical company GSK on Monday said it had agreed to buy a US company that specialises in the treatment of rare gastrointestinal cancer GIST. GSK said in a statement that it had agreed ...

More about GlaxoSmithKline GSK plc is a global healthcare company based in the United Kingdom, primarily engaged in the research, development, and manufacturing of pharmaceutical products.

Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks GlaxoSmithKline ( (GB:GSK)) has issued an update. GSK has made an application to the Financial Conduct Authority ...

A design team including Haworth Tompkins, Metropolitan Workshop, dRMM and Studio Egret West is drawing up a major redevelopment plan for GlaxoSmithKline’s (GSK’s) former west London HQ The project ...

In a deal that could potentially be worth up to US$820 million, GlaxoSmithKline (GSK) has gained the exclusive, worldwide development and commercialization rights to retigabine, a first-in-class ...